TrialBMC cancer2018

A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment.

Janet Hardy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.